| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Extracorporeal Membrane Oxygenation | 17 | 2024 | 653 | 3.860 |
Why?
|
| Heparin | 16 | 2023 | 229 | 2.710 |
Why?
|
| Anticoagulants | 19 | 2024 | 628 | 2.410 |
Why?
|
| Thrombosis | 12 | 2023 | 544 | 2.370 |
Why?
|
| Hemorrhage | 12 | 2024 | 517 | 2.350 |
Why?
|
| Blood Coagulation | 12 | 2023 | 135 | 2.000 |
Why?
|
| Antithrombins | 7 | 2024 | 61 | 1.860 |
Why?
|
| Thrombelastography | 7 | 2021 | 59 | 1.780 |
Why?
|
| Partial Thromboplastin Time | 7 | 2021 | 50 | 1.700 |
Why?
|
| Hemostasis | 8 | 2024 | 72 | 1.670 |
Why?
|
| Heart-Assist Devices | 11 | 2024 | 1099 | 1.530 |
Why?
|
| Blood Coagulation Disorders | 7 | 2021 | 110 | 1.490 |
Why?
|
| Hirudins | 5 | 2024 | 40 | 1.340 |
Why?
|
| Erythrocyte Transfusion | 7 | 2025 | 136 | 1.210 |
Why?
|
| Hemostatics | 4 | 2021 | 62 | 1.200 |
Why?
|
| Blood Coagulation Tests | 9 | 2021 | 62 | 1.180 |
Why?
|
| Drug Monitoring | 5 | 2020 | 185 | 1.150 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2020 | 358 | 1.120 |
Why?
|
| von Willebrand Diseases | 4 | 2019 | 55 | 1.110 |
Why?
|
| Factor VIII | 4 | 2020 | 48 | 0.990 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 4 | 2015 | 57 | 0.980 |
Why?
|
| Peptide Fragments | 6 | 2024 | 828 | 0.960 |
Why?
|
| ADAM Proteins | 3 | 2015 | 87 | 0.950 |
Why?
|
| Thrombophilia | 3 | 2022 | 42 | 0.880 |
Why?
|
| Rh-Hr Blood-Group System | 2 | 2014 | 12 | 0.860 |
Why?
|
| Citrates | 1 | 2024 | 24 | 0.850 |
Why?
|
| Citric Acid | 1 | 2024 | 38 | 0.840 |
Why?
|
| Plasma | 3 | 2020 | 105 | 0.840 |
Why?
|
| Factor Xa | 3 | 2017 | 19 | 0.810 |
Why?
|
| Blood Transfusion | 4 | 2022 | 296 | 0.770 |
Why?
|
| Fetal Blood | 3 | 2016 | 177 | 0.770 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2023 | 1162 | 0.750 |
Why?
|
| Factor V | 3 | 2022 | 16 | 0.740 |
Why?
|
| Humans | 94 | 2025 | 133496 | 0.720 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2021 | 29 | 0.690 |
Why?
|
| Child | 42 | 2024 | 25875 | 0.660 |
Why?
|
| Fibrinogen | 6 | 2024 | 163 | 0.660 |
Why?
|
| Blood Grouping and Crossmatching | 3 | 2014 | 17 | 0.640 |
Why?
|
| Infant, Newborn | 19 | 2024 | 8633 | 0.640 |
Why?
|
| Blood Platelets | 7 | 2020 | 336 | 0.600 |
Why?
|
| Hemoglobins | 3 | 2015 | 322 | 0.590 |
Why?
|
| Placenta Accreta | 5 | 2019 | 169 | 0.580 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 3 | 2014 | 39 | 0.550 |
Why?
|
| Menorrhagia | 3 | 2013 | 82 | 0.550 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 470 | 0.550 |
Why?
|
| Whole Blood Coagulation Time | 3 | 2014 | 14 | 0.540 |
Why?
|
| Recombinant Proteins | 5 | 2023 | 1431 | 0.540 |
Why?
|
| Vitamin K Deficiency | 1 | 2016 | 3 | 0.510 |
Why?
|
| International Normalized Ratio | 1 | 2016 | 45 | 0.500 |
Why?
|
| Vitamin K | 1 | 2016 | 39 | 0.500 |
Why?
|
| Retrospective Studies | 31 | 2025 | 17564 | 0.490 |
Why?
|
| Child, Preschool | 28 | 2024 | 14896 | 0.490 |
Why?
|
| Warfarin | 3 | 2012 | 134 | 0.490 |
Why?
|
| Infant | 23 | 2024 | 13254 | 0.480 |
Why?
|
| Protein Precursors | 1 | 2016 | 155 | 0.470 |
Why?
|
| Thrombocytopenia | 2 | 2014 | 235 | 0.470 |
Why?
|
| Female | 51 | 2024 | 71529 | 0.460 |
Why?
|
| Heart Defects, Congenital | 3 | 2023 | 1888 | 0.450 |
Why?
|
| Zika Virus Infection | 1 | 2017 | 175 | 0.450 |
Why?
|
| Infusions, Parenteral | 1 | 2014 | 94 | 0.450 |
Why?
|
| alpha-2-Antiplasmin | 1 | 2014 | 5 | 0.440 |
Why?
|
| Fibrinolysin | 1 | 2014 | 12 | 0.440 |
Why?
|
| Health Information Systems | 1 | 2014 | 35 | 0.430 |
Why?
|
| Hysterectomy | 5 | 2019 | 201 | 0.430 |
Why?
|
| Bilirubin | 1 | 2014 | 131 | 0.430 |
Why?
|
| Factor Xa Inhibitors | 1 | 2014 | 69 | 0.430 |
Why?
|
| Plasma Exchange | 3 | 2018 | 89 | 0.420 |
Why?
|
| Anemia, Sickle Cell | 3 | 2025 | 346 | 0.410 |
Why?
|
| Blood Banks | 2 | 2015 | 11 | 0.410 |
Why?
|
| Peptide Hydrolases | 1 | 2014 | 149 | 0.410 |
Why?
|
| von Willebrand Factor | 5 | 2024 | 205 | 0.400 |
Why?
|
| Platelet Function Tests | 5 | 2015 | 41 | 0.390 |
Why?
|
| beta-Alanine | 1 | 2012 | 6 | 0.390 |
Why?
|
| Gene Frequency | 1 | 2014 | 750 | 0.390 |
Why?
|
| Blood Platelet Disorders | 1 | 2012 | 14 | 0.390 |
Why?
|
| Riots | 1 | 2012 | 2 | 0.380 |
Why?
|
| Blood Safety | 1 | 2012 | 4 | 0.380 |
Why?
|
| Blood Loss, Surgical | 5 | 2019 | 158 | 0.380 |
Why?
|
| Adolescent | 24 | 2023 | 20587 | 0.360 |
Why?
|
| Benzimidazoles | 1 | 2012 | 136 | 0.360 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2012 | 286 | 0.360 |
Why?
|
| Male | 36 | 2024 | 65636 | 0.340 |
Why?
|
| Blood Coagulation Factor Inhibitors | 1 | 2010 | 2 | 0.340 |
Why?
|
| Disseminated Intravascular Coagulation | 3 | 2022 | 67 | 0.320 |
Why?
|
| Thrombin | 1 | 2010 | 62 | 0.320 |
Why?
|
| Preoperative Care | 1 | 2012 | 373 | 0.320 |
Why?
|
| Alleles | 1 | 2014 | 1694 | 0.310 |
Why?
|
| Egypt | 3 | 2014 | 30 | 0.310 |
Why?
|
| Databases, Factual | 1 | 2014 | 1257 | 0.310 |
Why?
|
| Biomarkers | 2 | 2016 | 3417 | 0.310 |
Why?
|
| Prothrombin Time | 4 | 2016 | 38 | 0.300 |
Why?
|
| Platelet Transfusion | 3 | 2019 | 54 | 0.290 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 394 | 0.290 |
Why?
|
| Blood Component Removal | 2 | 2012 | 35 | 0.280 |
Why?
|
| Prospective Studies | 8 | 2024 | 6584 | 0.270 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2007 | 7 | 0.270 |
Why?
|
| Enoxaparin | 2 | 2017 | 49 | 0.270 |
Why?
|
| Fibrinolytic Agents | 2 | 2020 | 209 | 0.260 |
Why?
|
| Adult | 18 | 2024 | 31767 | 0.260 |
Why?
|
| Hemolysis | 2 | 2025 | 114 | 0.260 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2007 | 152 | 0.260 |
Why?
|
| Serologic Tests | 1 | 2007 | 130 | 0.260 |
Why?
|
| Stroke | 3 | 2023 | 1078 | 0.250 |
Why?
|
| Aspirin | 2 | 2008 | 232 | 0.250 |
Why?
|
| Heart Transplantation | 2 | 2023 | 887 | 0.250 |
Why?
|
| Antithrombin III | 2 | 2017 | 28 | 0.240 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2009 | 292 | 0.240 |
Why?
|
| Immunologic Factors | 1 | 2007 | 185 | 0.240 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 2310 | 0.240 |
Why?
|
| Treatment Outcome | 11 | 2025 | 13089 | 0.240 |
Why?
|
| Prothrombin | 2 | 2016 | 26 | 0.240 |
Why?
|
| Heart Failure | 3 | 2023 | 2428 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 1344 | 0.230 |
Why?
|
| Age Factors | 6 | 2018 | 2955 | 0.230 |
Why?
|
| Hypersensitivity | 2 | 2021 | 195 | 0.230 |
Why?
|
| Blood Group Incompatibility | 3 | 2018 | 27 | 0.230 |
Why?
|
| Pregnancy | 9 | 2022 | 7591 | 0.220 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2003 | 6 | 0.220 |
Why?
|
| Protein S | 2 | 2016 | 9 | 0.210 |
Why?
|
| Protein C | 2 | 2016 | 21 | 0.210 |
Why?
|
| Young Adult | 8 | 2023 | 9968 | 0.200 |
Why?
|
| ABO Blood-Group System | 2 | 2018 | 66 | 0.200 |
Why?
|
| Activated Protein C Resistance | 1 | 2022 | 2 | 0.200 |
Why?
|
| Cerebrovascular Disorders | 1 | 2003 | 124 | 0.200 |
Why?
|
| Delphi Technique | 1 | 2024 | 241 | 0.200 |
Why?
|
| Time Factors | 6 | 2022 | 6545 | 0.200 |
Why?
|
| Fibrinolysis | 2 | 2014 | 44 | 0.190 |
Why?
|
| Protein C Deficiency | 1 | 2022 | 12 | 0.190 |
Why?
|
| Blood Chemical Analysis | 2 | 2014 | 88 | 0.190 |
Why?
|
| Isoantibodies | 2 | 2013 | 59 | 0.190 |
Why?
|
| Immunization, Passive | 1 | 2022 | 129 | 0.180 |
Why?
|
| Referral and Consultation | 1 | 2005 | 573 | 0.180 |
Why?
|
| Afibrinogenemia | 1 | 2021 | 10 | 0.180 |
Why?
|
| Critical Illness | 2 | 2024 | 628 | 0.180 |
Why?
|
| Syndrome | 2 | 2025 | 1173 | 0.170 |
Why?
|
| Cesarean Section | 4 | 2019 | 403 | 0.170 |
Why?
|
| Pregnancy Trimesters | 1 | 2021 | 34 | 0.170 |
Why?
|
| Postpartum Hemorrhage | 2 | 2019 | 109 | 0.170 |
Why?
|
| Heparitin Sulfate | 1 | 2020 | 21 | 0.170 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2020 | 14 | 0.170 |
Why?
|
| Nervous System Diseases | 1 | 2024 | 411 | 0.170 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2022 | 145 | 0.160 |
Why?
|
| Coagulants | 1 | 2019 | 8 | 0.160 |
Why?
|
| Quality Assurance, Health Care | 2 | 2012 | 221 | 0.160 |
Why?
|
| Anaphylaxis | 1 | 2021 | 87 | 0.160 |
Why?
|
| Liver Failure | 1 | 2020 | 91 | 0.160 |
Why?
|
| Hypocalcemia | 1 | 2019 | 38 | 0.150 |
Why?
|
| Factor IX | 3 | 2023 | 15 | 0.150 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 806 | 0.150 |
Why?
|
| Blood Coagulation Factors | 2 | 2023 | 35 | 0.150 |
Why?
|
| Materials Testing | 1 | 2018 | 77 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2018 | 1191 | 0.140 |
Why?
|
| Exercise | 1 | 2024 | 873 | 0.140 |
Why?
|
| Models, Biological | 3 | 2017 | 1530 | 0.140 |
Why?
|
| Surface Properties | 1 | 2018 | 96 | 0.140 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 134 | 0.140 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2018 | 54 | 0.140 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2019 | 486 | 0.140 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2022 | 423 | 0.140 |
Why?
|
| Clinical Protocols | 2 | 2018 | 244 | 0.140 |
Why?
|
| Prosthesis Implantation | 1 | 2018 | 152 | 0.130 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 3758 | 0.130 |
Why?
|
| Thromboembolism | 1 | 2017 | 93 | 0.130 |
Why?
|
| ADAMTS13 Protein | 2 | 2014 | 67 | 0.130 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2016 | 20 | 0.130 |
Why?
|
| Staphylococcus aureus | 2 | 2012 | 480 | 0.120 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 134 | 0.120 |
Why?
|
| Blood Donors | 2 | 2015 | 61 | 0.120 |
Why?
|
| Pediatrics | 1 | 2005 | 1218 | 0.120 |
Why?
|
| Inventories, Hospital | 1 | 2015 | 1 | 0.120 |
Why?
|
| Platelet Adhesiveness | 1 | 2015 | 40 | 0.120 |
Why?
|
| Drug Resistance | 2 | 2008 | 263 | 0.120 |
Why?
|
| Blood Preservation | 1 | 2015 | 30 | 0.120 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 1206 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 541 | 0.120 |
Why?
|
| Ventricular Function, Left | 1 | 2018 | 542 | 0.120 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2015 | 29 | 0.110 |
Why?
|
| Term Birth | 1 | 2015 | 34 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 1717 | 0.110 |
Why?
|
| Pipecolic Acids | 1 | 2014 | 8 | 0.110 |
Why?
|
| Staphylococcal Infections | 2 | 2012 | 573 | 0.110 |
Why?
|
| Placenta, Retained | 1 | 2014 | 12 | 0.110 |
Why?
|
| Thromboxane B2 | 1 | 2014 | 19 | 0.110 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 152 | 0.110 |
Why?
|
| Liver Transplantation | 2 | 2018 | 1101 | 0.110 |
Why?
|
| Cattle | 2 | 2018 | 586 | 0.110 |
Why?
|
| Leukocyte Transfusion | 1 | 2014 | 7 | 0.110 |
Why?
|
| Nutritional Status | 1 | 2016 | 327 | 0.110 |
Why?
|
| Cardiomyopathies | 1 | 2018 | 507 | 0.110 |
Why?
|
| Granulocytes | 1 | 2014 | 71 | 0.110 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2014 | 72 | 0.110 |
Why?
|
| Rho(D) Immune Globulin | 1 | 2013 | 12 | 0.100 |
Why?
|
| Postoperative Complications | 3 | 2023 | 3168 | 0.100 |
Why?
|
| Models, Theoretical | 1 | 2015 | 395 | 0.100 |
Why?
|
| Food-Drug Interactions | 1 | 2012 | 11 | 0.100 |
Why?
|
| Subcutaneous Tissue | 1 | 2012 | 16 | 0.100 |
Why?
|
| Dabigatran | 1 | 2012 | 28 | 0.100 |
Why?
|
| Drug Contamination | 1 | 2012 | 38 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2014 | 288 | 0.100 |
Why?
|
| Injections, Subcutaneous | 1 | 2012 | 130 | 0.100 |
Why?
|
| Pathology, Clinical | 1 | 2012 | 26 | 0.100 |
Why?
|
| Neutropenia | 1 | 2014 | 205 | 0.090 |
Why?
|
| Arginine | 1 | 2014 | 348 | 0.090 |
Why?
|
| Necrosis | 1 | 2012 | 211 | 0.090 |
Why?
|
| Seroepidemiologic Studies | 1 | 2012 | 144 | 0.090 |
Why?
|
| Hospitals, Urban | 1 | 2012 | 99 | 0.090 |
Why?
|
| Reference Values | 2 | 2015 | 725 | 0.090 |
Why?
|
| Laboratories | 1 | 2012 | 89 | 0.090 |
Why?
|
| Polysaccharides | 1 | 2012 | 152 | 0.090 |
Why?
|
| Hemodynamics | 1 | 2015 | 819 | 0.090 |
Why?
|
| Syphilis | 1 | 2012 | 98 | 0.090 |
Why?
|
| Outpatients | 2 | 2022 | 277 | 0.090 |
Why?
|
| Intraoperative Complications | 1 | 2012 | 164 | 0.090 |
Why?
|
| Heparin Lyase | 1 | 2010 | 2 | 0.090 |
Why?
|
| Osteoporosis | 1 | 2012 | 140 | 0.090 |
Why?
|
| Meconium Aspiration Syndrome | 1 | 2010 | 12 | 0.090 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2012 | 189 | 0.090 |
Why?
|
| Skin Diseases | 1 | 2012 | 136 | 0.090 |
Why?
|
| Coinfection | 1 | 2012 | 184 | 0.080 |
Why?
|
| Hepatitis B | 1 | 2012 | 171 | 0.080 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2010 | 99 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2011 | 378 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2012 | 714 | 0.080 |
Why?
|
| Incidence | 2 | 2015 | 3393 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2022 | 1268 | 0.080 |
Why?
|
| Artifacts | 1 | 2010 | 113 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 803 | 0.080 |
Why?
|
| Factor XII | 1 | 2009 | 4 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 1586 | 0.080 |
Why?
|
| Hemophilia B | 1 | 2009 | 8 | 0.080 |
Why?
|
| Polycythemia | 1 | 2009 | 45 | 0.070 |
Why?
|
| Middle Aged | 6 | 2024 | 29065 | 0.070 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2011 | 215 | 0.070 |
Why?
|
| Hepatitis C | 1 | 2012 | 388 | 0.070 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 676 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2011 | 466 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 774 | 0.070 |
Why?
|
| Wilms Tumor | 1 | 2009 | 119 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2024 | 3097 | 0.070 |
Why?
|
| Cardiac Catheterization | 1 | 2011 | 663 | 0.070 |
Why?
|
| Genotype | 1 | 2013 | 2715 | 0.070 |
Why?
|
| Pathology | 1 | 2007 | 38 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 3042 | 0.070 |
Why?
|
| Monitoring, Physiologic | 1 | 2009 | 379 | 0.060 |
Why?
|
| Risk Factors | 5 | 2019 | 10967 | 0.060 |
Why?
|
| Influenza, Human | 1 | 2012 | 700 | 0.060 |
Why?
|
| Sepsis | 1 | 2010 | 522 | 0.060 |
Why?
|
| Hypertension, Pulmonary | 1 | 2010 | 476 | 0.060 |
Why?
|
| Erythrocyte Count | 1 | 2005 | 23 | 0.060 |
Why?
|
| Erythrocyte Indices | 1 | 2005 | 17 | 0.060 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2005 | 20 | 0.060 |
Why?
|
| Anemia, Hemolytic | 1 | 2005 | 32 | 0.060 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2005 | 13 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2009 | 964 | 0.060 |
Why?
|
| Transfusion Reaction | 1 | 2025 | 39 | 0.060 |
Why?
|
| Mycophenolic Acid | 1 | 2005 | 58 | 0.060 |
Why?
|
| Rodenticides | 1 | 2004 | 1 | 0.060 |
Why?
|
| Hematuria | 1 | 2004 | 55 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2014 | 5205 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 1 | 2004 | 81 | 0.050 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 174 | 0.050 |
Why?
|
| Factor VIIa | 1 | 2023 | 24 | 0.050 |
Why?
|
| Patient Care Team | 2 | 2019 | 578 | 0.050 |
Why?
|
| Ischemic Attack, Transient | 1 | 2003 | 66 | 0.050 |
Why?
|
| Osteomyelitis | 1 | 2006 | 214 | 0.050 |
Why?
|
| Neovascularization, Physiologic | 1 | 2024 | 224 | 0.050 |
Why?
|
| Hospitals, Pediatric | 2 | 2019 | 794 | 0.050 |
Why?
|
| Animals | 4 | 2018 | 36120 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2024 | 240 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2024 | 446 | 0.050 |
Why?
|
| Platelet Aggregation | 2 | 2013 | 120 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 2 | 2015 | 787 | 0.040 |
Why?
|
| Body Weight | 2 | 2017 | 1035 | 0.040 |
Why?
|
| Prognosis | 2 | 2021 | 5052 | 0.040 |
Why?
|
| Body Weights and Measures | 1 | 2019 | 42 | 0.040 |
Why?
|
| Fibrin | 1 | 2020 | 64 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 1463 | 0.040 |
Why?
|
| Half-Life | 1 | 2019 | 162 | 0.040 |
Why?
|
| HIV Infections | 1 | 2012 | 2023 | 0.040 |
Why?
|
| Obesity | 1 | 2011 | 2438 | 0.040 |
Why?
|
| Inpatients | 1 | 2003 | 552 | 0.040 |
Why?
|
| Blood Component Transfusion | 1 | 2019 | 58 | 0.040 |
Why?
|
| Placenta Previa | 1 | 2019 | 67 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 270 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2019 | 3448 | 0.040 |
Why?
|
| Platelet Activation | 1 | 2018 | 71 | 0.040 |
Why?
|
| Equipment Design | 1 | 2020 | 598 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 2153 | 0.030 |
Why?
|
| Biological Variation, Population | 1 | 2017 | 27 | 0.030 |
Why?
|
| Benchmarking | 1 | 2018 | 146 | 0.030 |
Why?
|
| Isotonic Solutions | 1 | 2017 | 36 | 0.030 |
Why?
|
| Device Removal | 1 | 2018 | 224 | 0.030 |
Why?
|
| Body Composition | 1 | 2019 | 564 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2019 | 707 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2018 | 463 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 569 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2018 | 663 | 0.030 |
Why?
|
| Integrin alpha2 | 1 | 2015 | 10 | 0.030 |
Why?
|
| Erythrocyte Aging | 1 | 2015 | 8 | 0.030 |
Why?
|
| Algorithms | 2 | 2013 | 1730 | 0.030 |
Why?
|
| Birth Weight | 1 | 2017 | 355 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1179 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2018 | 566 | 0.030 |
Why?
|
| Immune System | 1 | 2015 | 97 | 0.030 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2013 | 9 | 0.030 |
Why?
|
| Antibodies | 1 | 2015 | 373 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 177 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2017 | 424 | 0.030 |
Why?
|
| Antifibrinolytic Agents | 1 | 2013 | 41 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2014 | 249 | 0.030 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2019 | 1008 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 300 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2015 | 653 | 0.030 |
Why?
|
| Autopsy | 1 | 2013 | 119 | 0.030 |
Why?
|
| Platelet Count | 1 | 2013 | 141 | 0.030 |
Why?
|
| Gestational Age | 1 | 2017 | 1230 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2013 | 328 | 0.020 |
Why?
|
| Software | 1 | 2017 | 732 | 0.020 |
Why?
|
| Medical Audit | 1 | 2012 | 104 | 0.020 |
Why?
|
| Glomerular Basement Membrane | 1 | 2011 | 9 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 604 | 0.020 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2011 | 20 | 0.020 |
Why?
|
| Glomerulonephritis | 1 | 2011 | 75 | 0.020 |
Why?
|
| Medical Records | 1 | 2011 | 193 | 0.020 |
Why?
|
| Acute Disease | 1 | 2014 | 1183 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2012 | 212 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 3668 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2015 | 621 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2011 | 182 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2013 | 539 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5451 | 0.020 |
Why?
|
| Hospitalization | 1 | 2017 | 1909 | 0.020 |
Why?
|
| Epidemiologic Measurements | 1 | 2008 | 3 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2011 | 247 | 0.020 |
Why?
|
| Length of Stay | 1 | 2014 | 1392 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2009 | 296 | 0.020 |
Why?
|
| Factor XI | 1 | 2007 | 3 | 0.020 |
Why?
|
| Chemistry, Clinical | 1 | 2007 | 13 | 0.020 |
Why?
|
| Quality Control | 1 | 2007 | 123 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 1320 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 6336 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2010 | 349 | 0.020 |
Why?
|
| Methicillin Resistance | 1 | 2006 | 118 | 0.020 |
Why?
|
| Graft vs Host Reaction | 1 | 2005 | 11 | 0.010 |
Why?
|
| Aged | 1 | 2024 | 21570 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2011 | 1714 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2009 | 734 | 0.010 |
Why?
|
| Community-Acquired Infections | 1 | 2006 | 247 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2006 | 190 | 0.010 |
Why?
|
| United States | 2 | 2011 | 11759 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2012 | 3725 | 0.010 |
Why?
|
| Tissue Donors | 1 | 2005 | 507 | 0.010 |
Why?
|
| Prevalence | 1 | 2008 | 2678 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 2190 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2009 | 4826 | 0.010 |
Why?
|
| Mice | 1 | 2009 | 18910 | 0.010 |
Why?
|